Clin Infect Dis :加州大学旧金山分校研究人员发现新冠患者体内抗体亲和力指数特征

2020-09-24 北京义翘神州 生物探索

在新冠免疫相关的研究中,SARS-CoV-2抗体的研究已经成为重点。大多数有症状患者在症状发生的两周之内可检测到SARS-CoV-2抗体,并且重症与非重症患者的血清抗体浓度在血清转换后呈现显着差异。

加州大学旧金山分校(UCSF)的科学家Dr. Yiqi Ruben Luo和Dr. Kara Lynch等利用非标记免疫分析技术开发一种测试SARS-COV-2的IgG抗体亲和力的新方法。

在新冠免疫相关的研究中,SARS-CoV-2抗体的研究已经成为重点。大多数有症状患者在症状发生的两周之内可检测到SARS-CoV-2抗体,并且重症患者与非重症患者的血清抗体浓度在血清转换后(即血清中检测到抗体的时间点)开始呈现统计学上的显着差异。除了浓度之外,衡量抗体的还有其他一些重要指标,包括亲和力、中和能力、亚型等。一般来说,高浓度和高亲和力的抗体具备较强的病毒中和能力,属于保护性抗体,但是有些低浓度和低亲和力的抗体也可以促进疾病的进展。

加州大学旧金山分校(UCSF)的科学家Dr. Yiqi Ruben Luo和Dr. Kara Lynch等利用非标记免疫分析技术开发一种测试SARS-COV-2的IgG抗体亲和力的新方法。相关研究成果已经被Clinical Infectious Diseases接收。

研究人员利用非标记免疫分析技术研发出一种新型的检测方法来测试SARS-COV-2的IgG抗体亲和力,用此方法研究了来自90位患者的168个从诊断初期至恢复期的血清样品。结果发现,IgG亲和力与发病后天数之间有很强的相关性(图A),对于个体患者来说,IgG亲和力随着时间的增加而增强(图B),在发病一个月之后,来自ICU患者的血清样品的IgG亲和力高于非ICU患者(图C)。

在新冠免疫相关的研究中,SARS-CoV-2抗体的研究已经成为重点。大多数有症状患者在症状发生的两周之内可检测到SARS-CoV-2抗体,并且重症患者与非重症患者的血清抗体浓度在血清转换后(即血清中检测到抗体的时间点)开始呈现统计学上的显着差异。除了浓度之外,衡量抗体的还有其他一些重要指标,包括亲和力、中和能力、亚型等。一般来说,高浓度和高亲和力的抗体具备较强的病毒中和能力,属于保护性抗体,但是有些低浓度和低亲和力的抗体也可以促进疾病的进展。

加州大学旧金山分校(UCSF)的科学家Dr. Yiqi Ruben Luo和Dr. Kara Lynch等利用非标记免疫分析技术开发一种测试SARS-COV-2的IgG抗体亲和力的新方法。相关研究成果已经被Clinical Infectious Diseases接收。

研究人员利用非标记免疫分析技术研发出一种新型的检测方法来测试SARS-COV-2的IgG抗体亲和力,用此方法研究了来自90位患者的168个从诊断初期至恢复期的血清样品。结果发现,IgG亲和力与发病后天数之间有很强的相关性(图A),对于个体患者来说,IgG亲和力随着时间的增加而增强(图B),在发病一个月之后,来自ICU患者的血清样品的IgG亲和力高于非ICU患者(图C)。

此文章中采用的抗体亲和力检测方法基于TFI (Thin-Film Interferometry) 非标记免疫分析技术,可以直接观察免疫复合物随着时间的形成和解离过程。使用的探针涂有RBD重组蛋白(购自义翘神州)。血清样品在缓冲液中稀释10倍。抗体亲和力测定步骤主要包括:将探针侵入缓冲液中进行标准线测量,然后在探针上形成RBD-抗体免疫复合物,接着用缓冲液进行冲洗,最后与二抗(山羊抗体)形成RBD-抗体-二抗免疫复合物。

这是第一个对新冠病人抗体亲和力指数及其随时间变化趋势的研究。来自英国的最近研究显示,新冠患者体内抗体浓度和中和能力会随着时间增加而减弱,本研究团队也观察到同样的现象(结果未发表)。现有研究并没有发现抗体亲和力会随着时间的增加而下降,因此推断抗体浓度下降可能是抗体中和力下降的主要因素。

在新冠疫情的大流行中,生命科学领域的研究不断取得突破,对于病毒各方面的认知也在不断的加深。义翘神州作为生命科学研究领域的知名公司,在国庆节、中秋节来临之际,在祝愿祖国蓬勃发展之时,也将会为大家送上一份诚意满满的精神和经济双重壕礼。

原始出处:

Yiqi Ruben Luo, Indrani Chakraborty, Cassandra Yun, et al.Kinetics of SARS-CoV-2 Antibody Avidity Maturation and Association with Disease Severity.Clin Infect Dis. 2020 Sep 14;ciaa1389. doi: 10.1093/cid/ciaa1389.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906533, encodeId=f7c9190653394, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jun 11 13:03:51 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907621, encodeId=941f190e621a1, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Aug 20 05:03:51 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013482, encodeId=0e762013482c4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 29 12:03:51 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897784, encodeId=dad3189e7842e, content=<a href='/topic/show?id=791459256c7' target=_blank style='color:#2F92EE;'>#旧金山#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59256, encryptionId=791459256c7, topicName=旧金山)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Sun Jun 27 12:03:51 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028587, encodeId=95b1102858e66, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 24 19:03:51 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888029, encodeId=840a888029d5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adab5421329, createdName=ms9000001665987067, createdTime=Thu Sep 24 18:09:15 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906533, encodeId=f7c9190653394, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jun 11 13:03:51 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907621, encodeId=941f190e621a1, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Aug 20 05:03:51 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013482, encodeId=0e762013482c4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 29 12:03:51 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897784, encodeId=dad3189e7842e, content=<a href='/topic/show?id=791459256c7' target=_blank style='color:#2F92EE;'>#旧金山#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59256, encryptionId=791459256c7, topicName=旧金山)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Sun Jun 27 12:03:51 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028587, encodeId=95b1102858e66, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 24 19:03:51 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888029, encodeId=840a888029d5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adab5421329, createdName=ms9000001665987067, createdTime=Thu Sep 24 18:09:15 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906533, encodeId=f7c9190653394, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jun 11 13:03:51 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907621, encodeId=941f190e621a1, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Aug 20 05:03:51 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013482, encodeId=0e762013482c4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 29 12:03:51 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897784, encodeId=dad3189e7842e, content=<a href='/topic/show?id=791459256c7' target=_blank style='color:#2F92EE;'>#旧金山#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59256, encryptionId=791459256c7, topicName=旧金山)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Sun Jun 27 12:03:51 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028587, encodeId=95b1102858e66, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 24 19:03:51 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888029, encodeId=840a888029d5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adab5421329, createdName=ms9000001665987067, createdTime=Thu Sep 24 18:09:15 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906533, encodeId=f7c9190653394, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jun 11 13:03:51 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907621, encodeId=941f190e621a1, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Aug 20 05:03:51 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013482, encodeId=0e762013482c4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 29 12:03:51 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897784, encodeId=dad3189e7842e, content=<a href='/topic/show?id=791459256c7' target=_blank style='color:#2F92EE;'>#旧金山#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59256, encryptionId=791459256c7, topicName=旧金山)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Sun Jun 27 12:03:51 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028587, encodeId=95b1102858e66, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 24 19:03:51 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888029, encodeId=840a888029d5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adab5421329, createdName=ms9000001665987067, createdTime=Thu Sep 24 18:09:15 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
    2021-06-27 liuquan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1906533, encodeId=f7c9190653394, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jun 11 13:03:51 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907621, encodeId=941f190e621a1, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Aug 20 05:03:51 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013482, encodeId=0e762013482c4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 29 12:03:51 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897784, encodeId=dad3189e7842e, content=<a href='/topic/show?id=791459256c7' target=_blank style='color:#2F92EE;'>#旧金山#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59256, encryptionId=791459256c7, topicName=旧金山)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Sun Jun 27 12:03:51 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028587, encodeId=95b1102858e66, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 24 19:03:51 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888029, encodeId=840a888029d5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adab5421329, createdName=ms9000001665987067, createdTime=Thu Sep 24 18:09:15 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
    2020-09-24 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1906533, encodeId=f7c9190653394, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Fri Jun 11 13:03:51 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907621, encodeId=941f190e621a1, content=<a href='/topic/show?id=379fe3364c9' target=_blank style='color:#2F92EE;'>#研究人员#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73364, encryptionId=379fe3364c9, topicName=研究人员)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Fri Aug 20 05:03:51 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013482, encodeId=0e762013482c4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 29 12:03:51 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897784, encodeId=dad3189e7842e, content=<a href='/topic/show?id=791459256c7' target=_blank style='color:#2F92EE;'>#旧金山#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59256, encryptionId=791459256c7, topicName=旧金山)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Sun Jun 27 12:03:51 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028587, encodeId=95b1102858e66, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Thu Sep 24 19:03:51 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888029, encodeId=840a888029d5, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adab5421329, createdName=ms9000001665987067, createdTime=Thu Sep 24 18:09:15 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
    2020-09-24 ms9000001665987067

    好文章

    0

相关资讯

全球群雄逐鹿疫苗研发,Nature刊发新冠中和抗体研究助推研发进程

无论是疫苗的研发还是病毒血清学抗体靶点研究都在极力探索新冠肺炎治疗的可行性。

两种埃博拉疫苗有望11月面市

世界卫生组织日前表示,两种预防埃博拉病毒的疫苗最快可能在11月面市。在这同时,有专家指出,西非不少人对埃博拉病毒有免疫力,或许可以从这些人身上抽取抗体来医治患者。 据报道,近200名专家近日在世卫总部召开两天会议,探讨如何加快找到对抗埃博拉的方法。世卫助理总干事基尼宣布,目前医学界已研制两种预防埃博拉的疫苗,疫苗还须要进行初步的安全测试,料可在11月面市,而率先注射疫苗的将是站在抗病毒前线的医疗

bioRxiv:科学家成功分离高效抗新冠病毒抗体

3 月 27 日,清华大学宣布,该校与深圳市第三人民医院合作,成功分离了高效抗新冠病毒抗体,为治疗和预防新冠肺炎提供强有力的医学干预手段。该项成果已投《自然》并发表在预印本平台 bioRxiv。